ATE405263T1 - Anti-hiv-chinuklidinverbindungen - Google Patents

Anti-hiv-chinuklidinverbindungen

Info

Publication number
ATE405263T1
ATE405263T1 AT05857423T AT05857423T ATE405263T1 AT E405263 T1 ATE405263 T1 AT E405263T1 AT 05857423 T AT05857423 T AT 05857423T AT 05857423 T AT05857423 T AT 05857423T AT E405263 T1 ATE405263 T1 AT E405263T1
Authority
AT
Austria
Prior art keywords
infectivity
hiv
mammal
quinuclidine compounds
benzoylquinuclidine
Prior art date
Application number
AT05857423T
Other languages
English (en)
Inventor
Laurent Lecanu
Janet Greeson
Vassilios Papadopoulos
Original Assignee
Samaritan Pharmaceuticals Inc
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samaritan Pharmaceuticals Inc, Univ Georgetown filed Critical Samaritan Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE405263T1 publication Critical patent/ATE405263T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AT05857423T 2004-04-05 2005-04-01 Anti-hiv-chinuklidinverbindungen ATE405263T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55955004P 2004-04-05 2004-04-05
US59020904P 2004-07-22 2004-07-22

Publications (1)

Publication Number Publication Date
ATE405263T1 true ATE405263T1 (de) 2008-09-15

Family

ID=36793472

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05857423T ATE405263T1 (de) 2004-04-05 2005-04-01 Anti-hiv-chinuklidinverbindungen

Country Status (8)

Country Link
US (1) US20080194619A1 (de)
EP (1) EP1732547B1 (de)
JP (1) JP2007531792A (de)
AT (1) ATE405263T1 (de)
AU (1) AU2005327283A1 (de)
CA (1) CA2563109A1 (de)
DE (1) DE602005009158D1 (de)
WO (1) WO2006085890A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2758395A1 (de) * 2011-09-22 2014-07-30 Vertex Pharmaceuticals Inc. Verbindungen als cholinkinasehemmer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1631289A4 (de) * 2003-06-02 2010-06-02 Samaritan Pharmaceuticals Inc Anti-hiv-benzamid-verbindungen
MY144753A (en) * 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists

Also Published As

Publication number Publication date
DE602005009158D1 (de) 2008-10-02
CA2563109A1 (en) 2006-08-17
EP1732547B1 (de) 2008-08-20
JP2007531792A (ja) 2007-11-08
US20080194619A1 (en) 2008-08-14
WO2006085890A3 (en) 2006-12-07
AU2005327283A1 (en) 2006-08-17
EP1732547A2 (de) 2006-12-20
WO2006085890A2 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
MX2021009269A (es) Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
CY1119001T1 (el) Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για ανευ νοηματος καταστολη και τη θεραπεια ασθενειας
RU2013121788A (ru) Ингибиторы репликации вич
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
MX365007B (es) Uso de acido lipasa lisosomal para tratar la dificiencia de acido lipasa lisosomal en pacientes.
EA201491460A1 (ru) ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
WO2020033838A3 (en) Treatment of egfr-mutant cancer
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
BR112015009504A2 (pt) inibidores de rock
BR112014012054A2 (pt) métodos de tratamento com deferiprona
EA201300421A1 (ru) Комбинированная терапия для лечения инфекции hcv
SE0400184D0 (sv) New therapeutical use
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
MY134562A (en) Methods and compositions to treat conditions associated with neovascularization
RU2012108439A (ru) Способы лечения опухолей головного мозга
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
CY1118486T1 (el) Λαπατινιμπη για τη θεραπεια του καρκινου
EA201390398A1 (ru) Арилсульфонамиды для лечения заболеваний цнс
ATE405263T1 (de) Anti-hiv-chinuklidinverbindungen
DE602004030048D1 (de) Ffizienz
CL2021003303A1 (es) Tratamiento para sinucleinopatías.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties